Pneumocystis Pneumonia Flashcards

1
Q

What is Pneumocystis pneumonia (PCP) caused by?

A

Pneumocystis jirovecii

PCP is a clinical syndrome caused by the fungus Pneumocystis jirovecii, which was previously referred to as Pneumocystis carinii for the species infecting rats.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

At what age do two-thirds of healthy children have antibodies to P. jirovecii?

A

By age 2 to 4 years

Initial infection with P. jirovecii usually occurs in early childhood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How is Pneumocystis believed to spread?

A

Airborne route

Rodent studies and case clusters in immunosuppressed patients suggest airborne transmission.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What was the incidence of PCP among people with advanced HIV before prophylaxis and ART?

A

70% to 80%

The mortality rate in individuals despite anti-Pneumocystis therapy was 20% to 40%.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What percentage of PCP cases now occur in people with HIV who are unaware of their HIV status?

A

Most cases

Incidence has declined substantially with the use of PCP prophylaxis and ART.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the most common clinical manifestations of PCP in people with HIV?

A

Subacute onset of progressive dyspnea, fever, non-productive cough, chest discomfort

Symptoms worsen within days to weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the most characteristic laboratory abnormality in PCP?

A

Hypoxemia

It can range from mild to severe based on arterial oxygen partial pressure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does a chest radiograph typically show in PCP patients?

A

Diffuse, bilateral, symmetrical ‘ground-glass’ interstitial infiltrates

A normal chest radiograph may occur in people with early disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is required for a definitive diagnosis of PCP?

A

Histopathologic or cytopathologic demonstration of organisms

This can be done in tissue, bronchoalveolar lavage fluid, or induced sputum samples.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What method has replaced staining methods in many laboratories for diagnosing PCP?

A

Polymerase chain reaction (PCR)

PCR is highly sensitive and specific for detecting Pneumocystis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is 1,3 β-D-glucan and its relevance to PCP diagnosis?

A

A component of the cell wall of Pneumocystis cysts, often elevated in people with HIV who have PCP

The sensitivity of the β-glucan assay for diagnosis appears to be high.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the indication for initiating primary prophylaxis for PCP?

A

CD4 count 100–200 cells/mm3 with detectable plasma HIV RNA or CD4 count <100 cells/mm3

Patients on pyrimethamine-sulfadiazine for toxoplasmosis do not require additional prophylaxis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the preferred therapy for primary prophylaxis against PCP?

A

TMP-SMX, 1 DS tablet PO daily or 1 SS tablet PO daily

TMP-SMX also provides protection against toxoplasmosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What should be done if a patient with HIV has a CD4 count increased to ≥200 cells/mm3 for ≥3 months?

A

Consider discontinuing primary prophylaxis

This is contingent on the response to ART.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What alternative prophylactic regimens can be used for patients who cannot tolerate TMP-SMX?

A

Dapsone, aerosolized pentamidine, intravenous pentamidine, atovaquone

These regimens are for those with intolerance or severe renal dysfunction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What should be done for patients with life-threatening adverse reactions to TMP-SMX?

A

Permanently discontinue TMP-SMX

No rechallenge should occur in cases like Stevens-Johnson syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the recommendation for pregnant patients receiving PCP prophylaxis?

A

Continue chemoprophylaxis as for nonpregnant adults

TMP-SMX is the recommended agent, with consideration for supplemental folic acid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

True or False: Isolation is a standard practice to prevent PCP.

A

False

There is insufficient data to support isolation as standard practice.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is a common non-specific laboratory finding in PCP patients?

A

Elevation of lactate dehydrogenase levels >500 mg/dL

This finding is common but not specific to PCP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What should clinicians consider for patients with mild adverse reactions to TMP-SMX?

A

Continue TMP-SMX if clinically feasible

Reinstitution of therapy may be considered after resolution of the reaction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are the recommended alternatives for prophylaxis against PCP and toxoplasmosis for HIV patients who cannot tolerate TMP-SMX?

A

Dapsone plus pyrimethamine plus leucovorin or atovaquone

Dapsone alone and pentamidine have not shown activity against toxoplasmosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What should be checked prior to starting dapsone?

A

Glucose-6-phosphate dehydrogenase (G6PD) levels

G6PD deficiency poses risks of hemolysis and methemoglobinemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the utility of IV pentamidine as PCP prophylaxis primarily evaluated in?

A

Retrospective/observational studies in immunosuppressed patients without HIV

Experience in people with HIV is limited.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the recommendation for discontinuing primary prophylaxis for PCP in HIV patients?

A

Discontinue if CD4 counts increase from <200 to ≥200 cells/mm3 for ≥3 months

Most participants had a CD4 count >300 cells/mm3 at discontinuation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the preferred therapy for moderate-to-severe PCP?

A

TMP-SMX: TMP 15–20 mg/kg/day and SMX 75–100 mg/kg/day IV

May switch to oral formulation after clinical improvement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What adjunctive treatment is recommended for moderate-to-severe PCP based on specific criteria?

A

Corticosteroids

Criteria include PaO2 <70 mmHg or A-a gradient ≥35 mmHg.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the dosing schedule for prednisone in treating moderate-to-severe PCP?

A

Days 1–5: 40 mg PO twice daily; Days 6–10: 40 mg PO daily; Days 11–21: 20 mg PO daily

IV methylprednisolone can be given as 80% of prednisone dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the alternative therapies for mild-to-moderate PCP?

A

Dapsone plus TMP, primaquine plus clindamycin, atovaquone

Dapsone and primaquine should be used cautiously in G6PD deficiency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What should be monitored in pregnant persons receiving corticosteroids for PCP?

A

Maternal glucose levels and blood pressure, fetal growth

Corticosteroids can improve treatment outcomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What should be done if TMP-SMX is discontinued due to mild adverse reactions?

A

Consider reinstitution of therapy after the reaction has resolved

Can gradually increase dose or reduce frequency.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What is the recommended duration of therapy for PCP?

A

21 days

Shorter durations may be effective but have not been systematically studied.

32
Q

What is the treatment of choice for PCP?

A

TMP-SMX

Standard doses must be adjusted for abnormal renal function.

33
Q

True or False: Aerosolized pentamidine is recommended for treating PCP.

A

False

It has limited efficacy and is associated with more frequent relapse.

34
Q

What should be considered when initiating ART in patients with PCP?

A

Initiate within 2 weeks of diagnosis if possible

Early ART initiation is associated with lower incidence of AIDS progression or death.

35
Q

What is the preferred therapy for pregnant persons with moderate-to-severe PCP?

A

TMP-SMX

Risks associated with first-trimester exposure are outweighed by benefits.

36
Q

Fill in the blank: Patients with documented or suspected PCP and moderate-to-severe disease should receive ________ as soon as possible.

A

adjunctive corticosteroids

37
Q

What is a potential risk associated with primaquine use in pregnancy?

A

Hemolytic anemia in G6PD deficient fetuses

G6PD deficiency cannot be diagnosed antenatally.

38
Q

What should be done if a patient’s CD4 count decreases after stopping prophylaxis?

A

Reintroduce prophylaxis if CD4 count drops to 100 to 200 cells/mm3

Prophylaxis should always be reintroduced if CD4 drops below 100 cells/mm3.

39
Q

What should be monitored in people with HIV who have non-life-threatening adverse reactions to TMP-SMX?

A

Continue TMP-SMX if clinically feasible

Consider desensitization or reduced dosing if necessary.

40
Q

What was the median time to ART initiation for participants who delayed ART?

A

45 days

This was compared to a median of 12 days for those who initiated ART early.

41
Q

What is Paradoxical immune reconstitution inflammatory syndrome (IRIS)?

A

A rare condition following an episode of PCP characterized by fever and exacerbation of pulmonary symptoms

Most cases occur within weeks of the PCP episode.

42
Q

What are common adverse effects of TMP-SMX in people with HIV?

A
  • Rash (30% to 55%)
  • Fever (30% to 40%)
  • Leukopenia (30% to 40%)
  • Thrombocytopenia (15%)
  • Hepatitis (20%)
  • Azotemia (1% to 5%)

Severe reactions can include Stevens-Johnson syndrome and toxic epidermal necrolysis.

43
Q

What is the recommended management for clinical failure in PCP treatment?

A

Wait 4 to 8 days before switching therapy

This allows for the exclusion of other causes of clinical failure.

44
Q

What is the preferred therapy for secondary prophylaxis against PCP?

A

TMP-SMX, 1 DS tablet PO daily

This regimen also provides protection against toxoplasmosis.

45
Q

When should secondary prophylaxis for PCP be discontinued?

A
  • CD4 count increased from <200 to ≥200 cells/mm3 for ≥3 months due to ART
  • Consider if CD4 count is 100–200 cells/mm3 and HIV RNA is undetectable for 3 to 6 months

Discontinuation is supported by observational studies.

46
Q

What should be done if an episode of PCP occurs at a CD4 count >200 cells/mm3?

A

Consider continuing PCP prophylaxis for life

This is especially true if plasma HIV RNA is below the level of detection.

47
Q

What are alternative therapies for secondary prophylaxis if TMP-SMX is intolerable?

A
  • Dapsone
  • Atovaquone
  • Aerosolized or IV pentamidine

Dapsone can be combined with pyrimethamine and leucovorin.

48
Q

What is the definition of clinical failure in PCP treatment?

A

Lack of improvement or worsening of respiratory function documented by arterial blood gases after 4 to 8 days of treatment

This occurs in approximately 10% of people with HIV with mild-to-moderate PCP.

49
Q

What should be monitored during PCP therapy?

A

Treatment response and detection of toxicity

Follow-up includes assessment for early relapse.

50
Q

What are the indications for restarting secondary prophylaxis?

A
  • CD4 count <100 cells/mm3 regardless of HIV RNA
  • CD4 count 100–200 cells/mm3 with HIV RNA above detection limit

Restarting is crucial for those at risk of PCP recurrence.

51
Q

What considerations should be made for pregnant individuals regarding PCP prophylaxis?

A
  • Discuss deferring pregnancy until prophylaxis can be safely discontinued
  • Consider increasing folic acid to 4 mg/day if not deferring

TMP-SMX is recommended for prophylaxis, but alternatives are suggested during the first trimester.

52
Q

What are the most common adverse effects of alternative therapies for PCP?

A
  • Methemoglobinemia and hemolysis with dapsone
  • Rash and fever with dapsone
  • Azotemia and pancreatitis with pentamidine

Adverse effects vary by medication choice.

53
Q

What should be done if TMP-SMX is discontinued due to a mild adverse reaction?

A

Consider reinstituting therapy after resolution of the reaction

Gradual dose increase can facilitate desensitization.

54
Q

What is the risk associated with PCP during pregnancy?

A

Increased risk of PCP-associated mortality and all-cause pneumonia complications

Close monitoring for preterm labor is advised for those affected.

55
Q

What are alternative prophylactic regimens for first-trimester TMP-SMX exposure?

A

Aerosolized pentamidine or oral atovaquone

Dapsone should only be used if other alternatives are not available or tolerated due to concerns about hemolytic anemia.

56
Q

What is the classification of trimethoprim?

A

Folic acid antagonist

It acts as a dihydrofolate reductase inhibitor.

57
Q

What congenital anomalies are associated with first-trimester exposure to TMP-SMX?

A
  • Neural tube defects
  • Cardiovascular anomalies
  • Oral clefts
  • Urinary tract anomalies
  • Multiple anomalies
58
Q

What was the pooled prevalence of congenital anomalies found in a systematic review of TMP-SMX use in pregnancy?

A

3.5% (95% CI, 1.8% to 5.1%)

59
Q

What is the adjusted odds ratio (aOR) for spontaneous abortion associated with first-trimester TMP-SMX exposure?

A

2.94 (95% CI, 1.89–4.57)

60
Q

What is the recommended daily dosage of folic acid supplementation for women of reproductive potential?

A

0.4 mg/day

This is to reduce the risk of neural tube defects.

61
Q

What is the effect of higher doses of folic acid supplementation (4-6 mg/day)?

A
  • Less frequent neural tube defects
  • Fewer oral clefts
  • Reduced recurrent preeclampsia
62
Q

True or False: Higher doses of folic acid (4 mg/day) have been shown to reduce the risk of congenital malformations.

A

False

A clinical trial did not show an advantage of higher doses on congenital malformations.

63
Q

What is the effect of leucovorin when used with TMP-SMX?

A

Increased risk of therapeutic failure and death

64
Q

What is the preferred initial therapy for PCP during pregnancy?

A

TMP-SMX (AI)

65
Q

What should clinicians consider for pregnant patients on TMP-SMX?

A

Supplemental folic acid 4 mg/day

This should be given as soon as possible in the first trimester.

66
Q

What are the risks associated with long-term corticosteroid use in pregnancy?

A
  • Maternal hypertension
  • Preeclampsia
  • Hyperglycemia
  • Premature rupture of membranes
  • Intrauterine growth restriction
  • Infection
67
Q

What is the safety profile of clindamycin during pregnancy?

A

Considered safe for use throughout pregnancy (BIII)

68
Q

What should be monitored closely when corticosteroids are used during pregnancy?

A
  • Maternal glucose levels
  • Blood pressure
  • Fetal growth
69
Q

What is the recommendation regarding primaquine use in pregnant women?

A

Not to be administered due to the risk of hemolytic anemia in a G6PD-deficient fetus.

70
Q

What is the potential risk associated with dapsone use in the first trimester?

A

Hemolytic anemia in pregnant persons or exposed fetuses

71
Q

What is the association between TMP-SMX exposure and low birth weight?

A

Adjusted odds ratio of 1.61 (95% CI, 1.16–2.23)

72
Q

What is the pooled odds ratio for neural tube defects associated with first-trimester TMP-SMX exposure?

A

2.5 (95% CI, 1.4–4.3)

73
Q

Fill in the blank: The quality of evidence regarding pregnancy outcomes after TMP-SMX exposure was considered _______.

74
Q

What is the recommended follow-up for fetal anatomy in pregnant individuals exposed to TMP-SMX?

A

Ultrasound at 18 weeks to 20 weeks

75
Q

True or False: There have been cases of kernicterus reported in neonates after maternal ingestion of sulfonamides.